JP2022526914A5 - - Google Patents
Info
- Publication number
- JP2022526914A5 JP2022526914A5 JP2021557004A JP2021557004A JP2022526914A5 JP 2022526914 A5 JP2022526914 A5 JP 2022526914A5 JP 2021557004 A JP2021557004 A JP 2021557004A JP 2021557004 A JP2021557004 A JP 2021557004A JP 2022526914 A5 JP2022526914 A5 JP 2022526914A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- canagliflozin
- patient
- angiotensin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025052013A JP2025111453A (ja) | 2019-03-26 | 2025-03-26 | 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823719P | 2019-03-26 | 2019-03-26 | |
| US201962823724P | 2019-03-26 | 2019-03-26 | |
| US201962823722P | 2019-03-26 | 2019-03-26 | |
| US62/823,724 | 2019-03-26 | ||
| US62/823,719 | 2019-03-26 | ||
| US62/823,722 | 2019-03-26 | ||
| US201962835550P | 2019-04-18 | 2019-04-18 | |
| US62/835,550 | 2019-04-18 | ||
| PCT/EP2020/058415 WO2020193652A1 (en) | 2019-03-26 | 2020-03-25 | Canagliflozin for the treatment of diabetic patients with chronic kidney disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025052013A Division JP2025111453A (ja) | 2019-03-26 | 2025-03-26 | 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526914A JP2022526914A (ja) | 2022-05-27 |
| JP2022526914A5 true JP2022526914A5 (https=) | 2023-03-10 |
Family
ID=70050106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557004A Pending JP2022526914A (ja) | 2019-03-26 | 2020-03-25 | 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン |
| JP2025052013A Pending JP2025111453A (ja) | 2019-03-26 | 2025-03-26 | 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025052013A Pending JP2025111453A (ja) | 2019-03-26 | 2025-03-26 | 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220160739A1 (https=) |
| EP (1) | EP3946367A1 (https=) |
| JP (2) | JP2022526914A (https=) |
| CN (1) | CN113613659A (https=) |
| CA (1) | CA3134786A1 (https=) |
| MX (1) | MX2021011711A (https=) |
| TW (1) | TW202103709A (https=) |
| WO (1) | WO2020193652A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022216870A1 (en) * | 2021-04-07 | 2022-10-13 | Ur-1 Therapeutics, Inc. | Urat1 inhibitor, pharmaceutical compositions and uses thereof |
| CN117085009B (zh) * | 2023-10-20 | 2024-01-30 | 首都医科大学附属北京天坛医院 | 卡格列净对急性缺血性卒中的治疗作用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2531660T3 (es) | 2003-08-01 | 2015-03-18 | Mitsubishi Tanabe Pharma Corporation | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| AU2015210898A1 (en) * | 2014-01-31 | 2016-07-28 | Janssen Pharmaceutica Nv | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
-
2020
- 2020-03-24 TW TW109109737A patent/TW202103709A/zh unknown
- 2020-03-25 JP JP2021557004A patent/JP2022526914A/ja active Pending
- 2020-03-25 MX MX2021011711A patent/MX2021011711A/es unknown
- 2020-03-25 CN CN202080024296.4A patent/CN113613659A/zh active Pending
- 2020-03-25 EP EP20715019.4A patent/EP3946367A1/en active Pending
- 2020-03-25 US US17/440,990 patent/US20220160739A1/en not_active Abandoned
- 2020-03-25 CA CA3134786A patent/CA3134786A1/en active Pending
- 2020-03-25 WO PCT/EP2020/058415 patent/WO2020193652A1/en not_active Ceased
-
2025
- 2025-03-26 JP JP2025052013A patent/JP2025111453A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12409174B2 (en) | Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases | |
| JP2022530575A (ja) | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 | |
| TW202128157A (zh) | 使用vadadustat 之治療方法 | |
| US20220378802A1 (en) | Treatment of alcoholic hepatitis | |
| JP2017534634A (ja) | 体液貯留の予測因子を使用してｃｋｄを処置する方法 | |
| JP2022526914A5 (https=) | ||
| KR20170123704A (ko) | 제2형 당뇨병 환자의 치료 | |
| TWI888340B (zh) | 用於預防或治療貓之全身性疾病之血管收縮素ii受體拮抗劑 | |
| JP2018516267A (ja) | 代謝性疾患を治療するためのサクビトリルおよびバルサルタン | |
| Peters et al. | Renal and cardiovascular effects of irbesartan in dialysis patients-a randomized controlled trial protocol (SAFIR study) | |
| JP2022548214A (ja) | ビルダグリプチンとメトホルミンとの組み合わせ療法 | |
| CN116887843A (zh) | 用于降低接受维持性透析的患者中的草酸盐/酯水平的组合物和方法 | |
| US20250114363A1 (en) | Pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof for preventing or treating cardiovascular disease of subject having high serum uric acid level | |
| KR20210032437A (ko) | 심부전의 치료를 위한 신규한 약제학적 용도 | |
| WO2014034871A1 (ja) | 脂質異常症の予防又は治療薬 | |
| EA052076B1 (ru) | Комбинация зиботентана и дапаглифлозина для лечения хронического заболевания почек | |
| EA050364B1 (ru) | Комбинация зиботентана и дапаглифлозина для лечения хронического заболевания почек | |
| HK40090059A (zh) | 用於治疗慢性肾病的齐泊腾坦和达格列净的组合 | |
| Kothari et al. | Diabetes with Renal Insufficiency | |
| HK40117723A (zh) | 利用达格列净治疗射血分数降低的心力衰竭的方法 | |
| EA044411B1 (ru) | Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов |